个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Shen, L.[1] ; Chen, P.[2] ; Lu, J.[3] ; Wan, Y.[4] ; Zheng, Y.[5] ; Ye, F.[6] ; Yang, J.[7] ; Liu, Y.[8] ; Pan, H.[9] ; Chen, H.[10] ; Sun, M.[11,12] ; Fan, Q.[13] ; Yuan, Y.[14] ; Chen, K.[15] ; Sun, Z.[16] ; Tian, H.[16] ; Ye, X.[16] ; Peng, Z.[17] ;
机构： [1]Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol,Minist Educ Beijing, Beijing, Peoples R China [2]Ningxia Med Univ, Gen Hosp, Oncol, Yinchuan, Ningxia, Peoples R China [3]UESTC, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sch Med,Oncol Dept, Chengdu, Peoples R China [4]Jiangxi Canc Hosp, Oncol Dept, Nanchang, Jiangxi, Peoples R China [5]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China [6]Xiamen Univ, Affiliated Hosp 1, Med Oncol, Xiamen, Peoples R China [7]Fujian Canc Hosp, Med Oncol, Fuzhou, Peoples R China [8]Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China [9]Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Oncol Dept, Hangzhou, Peoples R China [10]Lanzhou Univ Second Hosp, Dept Tumor Ctr, Lanzhou, Peoples R China [11]Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China [12]Shadong First Med Univ, Cent Hosp, Jinan, Peoples R China [13]Zhengzhou Univ, Affiliated Hosp 1, Oncol, Zhengzhou, Peoples R China [14]Zhejiang Univ, Affiliated Hosp 2, Med Oncol, Sch Med, East Gate 1, Hangzhou, Peoples R China [15]Soochow Univ, Affiliated Hosp 1, Oncol, Suzhou, Peoples R China [16]AstraZeneca China Headquarters, R&D China, Shanghai, Peoples R China [17]Peking Univ, Canc Hosp & Inst, Dept HI Oncol, Beijing, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.307
ISSN：
基金：
AstraZeneca
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol,Minist Educ Beijing, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Shen L.,Chen P.,Lu J.,et al.Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial[J].ANNALS OF ONCOLOGY.2023,34:S1542-S1543.doi:10.1016/j.annonc.2023.10.307.
APA：
Shen, L.,Chen, P.,Lu, J.,Wan, Y.,Zheng, Y....&Peng, Z..(2023).Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial.ANNALS OF ONCOLOGY,34,
MLA：
Shen, L.,et al."Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial".ANNALS OF ONCOLOGY 34.(2023):S1542-S1543

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号